echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Hengrui Medicine introduced over 100 million US dollars!

    Hengrui Medicine introduced over 100 million US dollars!

    • Last Update: 2022-01-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On January 5, the website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China announced that Hengrui Medicine has submitted a new drug marketing application for SHR8008 capsules
    .
    SHR8008 is a new type of antifungal drug introduced by Hengrui Medicine from Mycovia Pharmaceuticals with over US$100 million

    .
    According to the press release issued by Hengrui Medicine earlier, it is speculated that the indication for SHR8008 capsules this application is acute vulvovaginal candidiasis

    .

    Screenshot source: CDE official website

    SHR8008 (oteseconazole) is a novel oral azole antifungal drug developed by Mycovia, which can inhibit the fungal CYP51 enzyme with high specificity
    .
    According to an earlier press release from Mycovia, SHR8008 is designed to have higher selectivity, fewer side effects and better efficacy than currently available antifungal drugs

    .

    In June 2019, Hengrui Medicine entered into a partnership with Mycovia and obtained the exclusive rights of the drug in Greater China (Mainland China, Hong Kong, Macau and Taiwan) to develop and commercialize SHR8008 for the treatment or prevention of a range of fungi Diseases, including recurrent vulvovaginitis candidiasis, onychomycosis, and invasive fungal infections
    .

    In November 2021, Hengrui Medicine announced that SHR8008 met the protocol-preset superiority standard in a Phase 3 clinical study called SHR8008-302
    .
    This is a randomized, double-blind, double-dummy, fluconazole parallel-controlled, multicenter Phase 3 clinical trial to evaluate the efficacy and safety of SHR8008 capsules in the treatment of acute vulvovaginal candidiasis (VVC)

    .
    A total of 322 subjects with acute vulvovaginal candidiasis were enrolled in the trial.
    The primary endpoint of the trial was the proportion of subjects who recovered from an acute vulvovaginal candidiasis attack at the 28-day visit

    .

    The results of the Phase 3 clinical study showed that the cure rate of SHR8008 in the treatment of acute vulvovaginal candidiasis was significantly better than that of the control group, reaching the primary endpoint of the trial
    .
    Hengrui Medicine stated in its announcement in November 2021 that the company will submit a communication application for the new drug listing of the drug to CDE in the near future

    .
    Therefore, it is speculated that the indication of SHR8008 capsules in this application is acute vulvovaginal candidiasis

    .

    In addition, Hengrui Medicine is conducting another randomized, double-blind, fluconazole-controlled, multicenter Phase 3 clinical trial called SHR8008-301, which aims to evaluate SHR8008 capsules in the treatment of recurrent vulvovaginal Candida Efficacy and safety of the disease (RVVC)
    .

    It is worth mentioning that in the United States, the FDA has accepted the new drug marketing application of oteseconazole for the treatment of recurrent vulvovaginal candidiasis and granted it priority review status, with a PDUFA target date of January 27, 2022
    .
    Mycovia said in a press release that, if approved, oteseconazole would be the first FDA-approved drug for the treatment of RVVC

    .
    In addition, the FDA has granted oteseconazole Qualified Infectious Disease Product Designation and Fast Track designation

    .

    Publicly available information shows that many women worldwide are affected by acute vulvovaginal candidiasis and recurrent vulvovaginal candidiasis
    .
    It is hoped that SHR8008 (oteseconazole) will be approved soon, bringing new treatment options to female patients

    .

    references:

    references:

    [1] China National Medical Products Administration Center for Drug Evaluation (CDE).
    Retrieved Jan 05, 2022, from https:// China National Medical Products Administration Center for Drug Evaluation (CDE).
    Retrieved Jan 05, 2022, from https:// [2] Mycovia Pharmaceuticals Announces Completion of Partner Jiangsu Hengrui Pharmaceuticals' Phase 3 Clinical Study Evaluating Oteseconazole for Treatment of Acute Vulvovaginal Candidiasis (VVC) in China Retrieved Nov.
    03, 2021, from https:// home/20211103005162/en

    [2] Mycovia Pharmaceuticals Announces Completion of Partner Jiangsu Hengrui Pharmaceuticals' Phase 3 Clinical Study Evaluating Oteseconazole for Treatment of Acute Vulvovaginal Candidiasis (VVC) in China Retrieved Nov.
    03, 2021, from https:// home/20211103005162/en

    [3] Hengrui Medicine's announcement on the introduction of products from Mycovia in the United States.
    Retrieved Jun 18, 2019, from http://data.
    eastmoney.
    com/notices/detail/600276/AN201906171335355287.
    html

    [3] Hengrui Medicine's announcement on the introduction of products from Mycovia in the United States.
    Retrieved Jun 18, 2019, from http://data.
    eastmoney.
    com/notices/detail/600276/AN201906171335355287.
    html

    [4] Announcement of Hengrui Medicine on the Progress of Drug Clinical Trials.
    Retrieved Nov.
    04, 2021, from http:// 11-05

    [4] Announcement of Hengrui Medicine on the Progress of Drug Clinical Trials.
    Retrieved Nov.
    04, 2021, from http:// 11-05
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.